Cardiovascular Disease Screening

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00483951
Recruitment Status : Suspended
First Posted : June 8, 2007
Last Update Posted : August 9, 2018
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) )

June 7, 2007
June 8, 2007
August 9, 2018
June 6, 2007
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00483951 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Cardiovascular Disease Screening
Suburban/NHLBI Cardiovascular Disease Screening Protocol

This study will evaluate volunteers 18 years of age and older to see if they qualify for one of NHLBI s research studies. Tests include the following:

  • General medical evaluation, which may include blood tests, chest x-ray, electrocardiogram (ECG) and echocardiogram (heart ultrasound).
  • Other tests as appropriate, such as magnetic resonance imaging (MRI), cardiac computed tomography (CT scan of the heart), nuclear stress test and echocardiography stress test.
  • X-ray contrast studies of the heart and blood vessels. (These may be excluded in patients with kidney risk factors.)

This is a screening protocol. This protocol allows two functions: 1) the protocol allows physicians in the Suburban/NHLBI Cardiovascular Imaging program to evaluate patients referred to the program with clinically indicated studies and research studies. 2) It is also designed to determine if patients may be suitable candidates for one of our NHLBI research protocols.

Patients greater than or equal to 18 years of age referred for possible cardiovascular disease will be enrolled in the protocol for a period of one year. At one year, patients will either be: 1) transferred to one of our specific research MRI or CT protocols, 2) removed from the screening protocol and made inactive, or 3) re-enrolled on the screening protocol with the patient s consent.

Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Congenital Heart Disease
  • Atherosclerosis
  • Myocardial Ischemia
  • Myocardial Infarction
  • Acquired Heart Disease
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
Not Provided

No one will be excluded from this study based on race, gender, or ethnicity.

A. General Inclusion Criteria:

  • Age greater than or equal to 18
  • Capable of giving informed consent.

B. General Exclusion Criteria (for all arms):

  • Pregnant women (uncertain patients will have urine or blood testing).
  • Decompensated heart failure (unable to lie flat in bed).

Test Specific Exclusion Criteria:

A. CT Exclusion Criteria (excludes contrast enhanced CT scan only):

  • Allergy to iodinated contrast agent excludes contrast enhanced CT research studies.
  • Multiple myeloma.
  • Patients with severe kidney disease (eGFR less than 30 mL/min/1.73 m(2).

B. Beta Antagonist Exclusions (excluded the use of beta blocker only):

  • Asthma or severe chronic lung disease/emphysema with regular use of inhaler.
  • Decompensated heart failure.

C. MRI Exclusion Criteria (excludes MRI scan only):

  • Cardiac pacemaker or implantable defibrillator.
  • Cerebral aneurysm clip.
  • Neural stimulator (e.g. TENS-Unit).
  • Any type of ear implant.
  • Metal in eye (e.g. from machining).
  • Any implanted device (e.g. insulin pump, drug infusion device).

D. Exclusions from MRI contrast agents:

  • Lactating women unless they are willing to discard breast milk for 24 hours.
  • Severe kidney disease (less than 30 mL/min/1.73 m(2).

E. Vasodilator Exclusions (excludes some vasodilator stress testing):

  • Asthma or chronic obstructive pulmonary disease (emphysema) actively treated with bronchodilators or leukotriene receptor antagonists (albuterol, seravent, atrovent, montelukast singulair, zafirlukast Accolate. These conditions only exclude adenosine and dipyridamole.
  • Second degree (Type II) and third degree atrioventricular heart block.

F. Exclusions from Dobutamine stress MRI only:

  • Severe problems with heart rhythms.
  • Severe high blood pressure.

G. Exclusion criteria for atropine (given during dobutamine stress echocardiography when target heart rate not achievable with dobutamine alone).

  • Narrow angle glaucoma.
  • Known or suspected severe bladder outlet obstruction due to prostatic hypertrophy.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) )
National Heart, Lung, and Blood Institute (NHLBI)
Not Provided
Principal Investigator: Andrew E Arai, M.D. National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health Clinical Center (CC)
April 6, 2018